Arthritis Research & Therapy

official impact factor 4.36

Open Access Highly Access Research article

Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study

Jennie Ursum1, Wouter H Bos1, Nancy van Dillen1, Ben AC Dijkmans1,2 and Dirkjan van Schaardenburg1,2*

Author Affiliations

1 Jan van Breemen Institute, department of rheumatology, Dr. Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands

2 VU University Medical Centre, department of rheumatology, Postbus 7057, 1007 MB Amsterdam, The Netherlands

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:R8 doi:10.1186/ar2907

Published: 12 January 2010

Abstract

Introduction

To investigate whether baseline levels of anti-citrullinated protein antibody (ACPA) or IgM rheumatoid factor (IgM-RF) and changes in the year thereafter are associated with disease activity, functional and radiographic outcome in early arthritis patients, and provide additional information over baseline autoantibody status.

Methods

In 545 early arthritis patients ACPA and IgM-RF levels, disease activity (DAS28), the Health Assessment Questionnaire (HAQ) and Sharp/Van der Heijde Score (SHS) were assessed annually. Baseline status, levels and first-year changes of the autoantibodies were associated with these measures at the two-year follow-up and sub-analysed according to autoantibody status.

Results

The mean age was 52.7 years, 69% was female, at baseline 56% was ACPA positive, 47% IgM-RF positive. At the two-year follow-up the mean DAS28 was 2.88, and the median HAQ and SHS were 0.38 and 1, respectively. At one year, ACPA and IgM-RF levels had decreased by 31% and 56%, respectively. A switch from negative to positive occurred in 2% for ACPA and 3% for IgM-RF. Positive ACPA and RF status were both associated with SHS at two years (P < 0.001), but baseline levels only showed a minor correlation of ACPA with DAS28 and HAQ at two years. Level changes were not associated with the outcome parameters.

Conclusions

Baseline levels and first-year changes of ACPA and IgM-RF are hardly associated with outcome after two years. Seroconversion seldom occurs. Therefore, it does not appear useful to repeat ACPA or IgM-RF measurements.